140 related articles for article (PubMed ID: 36307183)
1. Meropenem population pharmacokinetics and model-based dosing optimisation in patients with serious bacterial infection.
Murínová I; Švidrnoch M; Gucký T; Řezáč D; Hlaváč J; Slanař O; Šíma M
Eur J Hosp Pharm; 2024 Apr; 31(3):253-258. PubMed ID: 36307183
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation.
O'Jeanson A; Larcher R; Le Souder C; Djebli N; Khier S
Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):695-705. PubMed ID: 34403127
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetic Analysis of Meropenem After Intravenous Infusion in Korean Patients With Acute Infections.
Kim YK; Lee DH; Jeon J; Jang HJ; Kim HK; Jin K; Lim SN; Lee SS; Park BS; Kim YW; Shin JG; Kiem S
Clin Ther; 2018 Aug; 40(8):1384-1395. PubMed ID: 30093133
[TBL] [Abstract][Full Text] [Related]
4. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis.
Ehmann L; Zoller M; Minichmayr IK; Scharf C; Huisinga W; Zander J; Kloft C
Int J Antimicrob Agents; 2019 Sep; 54(3):309-317. PubMed ID: 31229669
[TBL] [Abstract][Full Text] [Related]
5. Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane.
Padullés Zamora A; Juvany Roig R; Leiva Badosa E; Sabater Riera J; Pérez Fernández XL; Cárdenas Campos P; Rigo Bonin R; Alía Ramos P; Tubau Quintano F; Sospedra Martinez E; Colom Codina H
J Antimicrob Chemother; 2019 Oct; 74(10):2979-2983. PubMed ID: 31335959
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Hemodialysis Effect on Pharmacokinetics of Meropenem/Vaborbactam in End-Stage Renal Disease Patients Using Modeling and Simulation.
Zhuang L; Yu Y; Wei X; Florian J; Jang SH; Reynolds KS; Wang Y
J Clin Pharmacol; 2020 Aug; 60(8):1011-1021. PubMed ID: 32149406
[TBL] [Abstract][Full Text] [Related]
7. Development of a dosing nomogram for continuous-infusion meropenem in critically ill patients based on a validated population pharmacokinetic model.
Minichmayr IK; Roberts JA; Frey OR; Roehr AC; Kloft C; Brinkmann A
J Antimicrob Chemother; 2018 May; 73(5):1330-1339. PubMed ID: 29425283
[TBL] [Abstract][Full Text] [Related]
8. Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
Burger R; Guidi M; Calpini V; Lamoth F; Decosterd L; Robatel C; Buclin T; Csajka C; Marchetti O
J Antimicrob Chemother; 2018 Dec; 73(12):3413-3422. PubMed ID: 30304491
[TBL] [Abstract][Full Text] [Related]
9. Comparison of two empirical prolonged infusion dosing regimens for meropenem in patients with septic shock: A two-center pilot study.
Eisert A; Lanckohr C; Frey J; Frey O; Wicha SG; Horn D; Ellger B; Schuerholz T; Marx G; Simon TP
Int J Antimicrob Agents; 2021 Mar; 57(3):106289. PubMed ID: 33515688
[TBL] [Abstract][Full Text] [Related]
10. A Nonparametric Pharmacokinetic Approach to Determine the Optimal Dosing Regimen for 30-Minute and 3-Hour Meropenem Infusions in Critically Ill Patients.
Mathew SK; Mathew BS; Neely MN; Naik GS; Prabha R; Jacob GG; K S; Fleming DH
Ther Drug Monit; 2016 Oct; 38(5):593-9. PubMed ID: 27454665
[TBL] [Abstract][Full Text] [Related]
11. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
[TBL] [Abstract][Full Text] [Related]
12. Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients.
Busse D; Simon P; Schmitt L; Petroff D; Dorn C; Dietrich A; Zeitlinger M; Huisinga W; Michelet R; Wrigge H; Kloft C
Clin Pharmacokinet; 2022 May; 61(5):655-672. PubMed ID: 34894344
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of standard-dose meropenem in critically ill patients on continuous renal replacement therapy: a prospective observational trial.
Onichimowski D; Będźkowska A; Ziółkowski H; Jaroszewski J; Borys M; Czuczwar M; Wiczling P
Pharmacol Rep; 2020 Jun; 72(3):719-729. PubMed ID: 32301057
[TBL] [Abstract][Full Text] [Related]
14. Towards a Generic Tool for Prediction of Meropenem Systemic and Infection-Site Exposure: A Physiologically Based Pharmacokinetic Model for Adult Patients with Pneumonia.
Thémans P; Marquet P; Winkin JJ; Musuamba FT
Drugs R D; 2019 Jun; 19(2):177-189. PubMed ID: 31090024
[TBL] [Abstract][Full Text] [Related]
15. Meropenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy.
Chaijamorn W; Rungkitwattanakul D; Pattharachayakul S; Singhan W; Charoensareerat T; Srisawat N
J Crit Care; 2020 Dec; 60():285-289. PubMed ID: 32949895
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of meropenem in critically ill children with different renal functions.
Rapp M; Urien S; Foissac F; Béranger A; Bouazza N; Benaboud S; Bille E; Zheng Y; Gana I; Moulin F; Lesage F; Renolleau S; Tréluyer JM; Hirt D; Oualha M
Eur J Clin Pharmacol; 2020 Jan; 76(1):61-71. PubMed ID: 31654149
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic/Pharmacodynamic Analysis of Meropenem for the Treatment of Nosocomial Pneumonia in Intracerebral Hemorrhage Patients by Monte Carlo Simulation.
Kong L; Tang Y; Zhang X; Lu G; Yu M; Shi Q; Wu X
Ann Pharmacother; 2017 Nov; 51(11):970-975. PubMed ID: 28677407
[TBL] [Abstract][Full Text] [Related]
18. Effects of i.v. push administration on β-lactam pharmacodynamics.
Butterfield-Cowper JM; Burgner K
Am J Health Syst Pharm; 2017 May; 74(9):e170-e175. PubMed ID: 28438821
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic–pharmacodynamic target attainment analysis of meropenem in Japanese adult patients.
Ikawa K; Morikawa N; Ohge H; Ikeda K; Sueda T; Taniwaki M; Kurisu K
J Infect Chemother; 2010 Feb; 16(1):25-32. PubMed ID: 20082106
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a non-parametric modelling for meropenem in critically ill patients using Monte Carlo simulation.
Idoate Grijalba AI; Aldaz Pastor A; Marquet P; Woillard JB
Eur J Clin Pharmacol; 2019 Oct; 75(10):1405-1414. PubMed ID: 31338539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
